Thin-film graphene cortical surface interface from INBRAIN, used intraoperatively in a first-in-human study at Manchester. Company release; contact counts not published in the sources read.
Independent, source-linked catalog sheet. Not a manufacturer-issued datasheet, regulatory decision or instructions for clinical use. Human evidence does not establish approval. Source-specific restrictions, conflicts and missing specifications are retained below.
INBRAIN graphene cortical interface
INBRAIN’s BCI is a flexible graphene thin film placed on the cortex during tumor surgery. The first four patients showed no device-related adverse events and high-gamma phoneme activity. This sheet uses company releases and the registry ID, so electrode geometry is Unreported.
Identity
Field
Value and source scope
Device
INBRAIN Neuroelectronics graphene BCI cortical film [1][2]
Manufacturer
INBRAIN Neuroelectronics, Barcelona; spin-off of ICN2 and CSIC [1][2]
Company device; first-in-human study sponsored by the University of Manchester [1]
First demonstrated
First human application announced September 27, 2024 [2]
First human implant
Unreported
Species studied
Human [1][2]
Regulatory status
Investigational; first-in-human study NCT06368310 [1]
Function
Brain signal monitoring and targeted stimulation during tumor surgery; high-gamma decoding for language mapping [1]
Target tissue
Cortical surface during awake brain tumor surgery [1]
Geometry and architecture
Field
Value and source scope
Interface type
Ultra-flexible thin-film graphene semiconductor with high-density, multiscale, bidirectional contacts and reduced graphene oxide nanoporous matrices [1]
Array layout
Unreported
Electrode count
Unreported
Pitch
Unreported
Electrode lengths
Unreported
Shank width and thickness
Unreported
Tip and exposed site geometry
Unreported
Contact coating
Unreported
Insulation
Unreported
Insertion method
Unreported
Anchoring and fixation
Unreported
Electrode and channel physics
Field
Value and source scope
Exposed site area
Unreported
Electrode material
Unreported
Impedance (with measurement frequency)
Unreported
Noise floor or SNR
Unreported
Recording modality
Unreported
Sampling rate
Unreported
Stimulation capability
Unreported
Charge injection limit
Unreported
Reference and ground
Unreported
Tissue interface and bioresponse
Field
Value and source scope
Target tissue
Unreported
Insertion trauma and BBB disruption
Unreported
Vascular disruption risk
Unreported
Micromotion sensitivity
Unreported
Gliosis and encapsulation
Unreported
Neuron loss near sites
Unreported
Foreign-body response mitigation
Unreported
Typical failure modes
Unreported
System architecture
Field
Value and source scope
Onboard electronics
Unreported
Data path
Unreported
Telemetry bandwidth
Unreported
Sampling rate
Unreported
Power
Unreported
Thermal management
Unreported
Packaging and hermeticity
Unreported
MRI compatibility
Unreported
Surgical complexity
Unreported
Output connectors
Unreported
Performance envelope
Field
Value and source scope
Acute yield
Unreported
Chronic yield
Unreported
Stability over time
Unreported
Longevity
Unreported
Revision and explant experience
Unreported
Adverse events
Unreported
Notable demonstrations
Unreported
Clinical and preclinical evidence
Field
Value and source scope
Human subjects
Interim analysis of the first four patients at the Manchester Centre for Clinical Neurosciences; the 2024 release said 8 to 10 patients were planned [1][2]
Preclinical cohort
Unreported
Follow-up duration
Unreported
Indications
Unreported
Trials and registries
NCT06368310, sponsor University of Manchester; chief investigator David Coope [1]
Primary outcomes
Company-reported: no device-related adverse events in the first four patients; during awake language mapping the device captured distinct high-gamma activity linked to different phonemes [1]
Key limitations
Intraoperative, short-term use in tumor surgery. Contact counts, pitch and dimensions were not in the sources read. Company release [1][2]
Engineering tradeoffs
Field
Value and source scope
Strengths
Unreported
Limitations
Unreported
Scaling constraints
Unreported
Version boundary
The configuration in the interim analysis of July 2025. Enrolment completion was announced in April 2026 but was not reviewed here.